Kodu・Aktsiate loetelu・Theravance Biopharma Inc

Theravance Biopharma Inc

Suletud

16.98 -0.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

17.01

Põhinäitajad
By Trading Economics
Sissetulek	-965K -5.9M
Müük	3M 21M
P/E Sektori keskmine	16.269 57.371
Aktsiakasum	0.07
Kasumimarginaal	-28.45
Töötajad	90
EBITDA	5.9M 839K

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.06% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	9. nov 2026

Turustatistika
By TradingEconomics
Turukapital	4.1M 878M
Eelmine avamishind	17.16
Eelmine sulgemishind	16.98

Theravance Biopharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid broader financial trends, while concerns over U.S. national debt and rising bond yields prompt Treasury interventions ahead of key economic data releases.

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid concerns over U.S. national debt and bond market pressures, while Asian stocks anticipate recovery following positive U.S. market performance.

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. national debt hits $40 trillion, prompting concerns over economic stability and upcoming key economic data releases.

23. aug 2026, 23:51 UTC

Cryptocurrency prices rise amid U.S. national debt concerns and bond market volatility, as investors brace for major earnings reports and geopolitical tensions.

23. aug 2026, 23:51 UTC

Australia's Construction Output Expected to Rise 0.4% Amid Cautious Investor Sentiment Ahead of August Release

23. aug 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI Release on August 26, 2026, Expected to Reveal Key Insights into Core Inflation Trends Amid Global Economic Uncertainty.

23. aug 2026, 23:51 UTC

Australia's Inflation Rate Expected to Drop Slightly to 3.2% Amid Economic Shifts and Market Volatility Concerns

23. aug 2026, 23:51 UTC

Macro News

Bitcoin is higher today, continuing its upward trend since Saturday. Positive sentiment follows Wall Street's rebound amid declining interest rates and rising gold prices.

23. aug 2026, 23:51 UTC

Japan's Industrial Production Data Release on August 30 Expected to Show Continued Growth Amid Market Concerns.

23. aug 2026, 23:51 UTC

Japan's Retail Sales YoY Data Release on August 30 Expected to Show Significant Rebound Amid Mixed Economic Sentiment and Recent Stock Market Decline.

23. aug 2026, 23:41 UTC

Canada's Monthly GDP Growth Expected Amid Trade Tensions and Inflation Concerns Ahead of August 28 Release.

23. aug 2026, 23:41 UTC

Bank of Korea's Upcoming Interest Rate Decision Sparks Optimism Amid KOSPI Rally and Global Economic Trends

23. aug 2026, 23:41 UTC

Canada's GDP Growth Rate Faces Caution Amid Escalating U.S. Trade Tensions and Tariff Concerns Ahead of August 28 Release

23. aug 2026, 23:41 UTC

Canada's Q2 2026 GDP Growth Rate Release Amidst U.S. Trade Tensions and Infrastructure Boosts Scheduled for August 28, Heightening Market Scrutiny.

23. aug 2026, 23:31 UTC

RBA Bulletin Release on August 27, 2026 Sparks Anticipation Amid Global Decline in Interest Rates and Market Fluctuations.

23. aug 2026, 23:21 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Amid Mixed Sentiment and Economic Growth Concerns

23. aug 2026, 23:21 UTC

U.S. Goods Trade Balance Expected to Hit $99 Billion Deficit Amid Rising U.S.-Canada Tariff Tensions

23. aug 2026, 23:21 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% in July Amid Mixed Market Sentiment Ahead of August Release

23. aug 2026, 23:21 UTC

Canada's Current Account Deficit Expected to Reach -5.5 Billion CAD in Q2 2026 Amid Trade Tensions with U.S.

23. aug 2026, 23:21 UTC

The CAD/CHF currency pair is lower during after-market hours, reflecting a decline since Friday's close amid notable fluctuations in its one-month trading range.

23. aug 2026, 23:21 UTC

Correlated Moves

XRP is rising during Sunday’s session, supported by Bitcoin's upward movement. The asset has gained significantly since Saturday and remains above its 20-day moving average.

23. aug 2026, 23:11 UTC

EUR/NZD is trading higher in after-market hours, continuing a gradual increase since Friday's close, despite a recent trend of lower closes.

23. aug 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Inflation and Economic Uncertainty, According to S&P/Case-Shiller Index

23. aug 2026, 23:11 UTC

U.S. GDP Price Index QoQ 2nd Estimate Set for August 26, Forecasting a 0.063% Increase Amid Inflation Concerns and Mixed Market Sentiment

23. aug 2026, 23:11 UTC

South Africa's Trade Balance Data Release on August 28 Expected Amid Fluctuating Trends and Commodity Market Sentiment.

23. aug 2026, 23:01 UTC

Correlated Moves

Gold/Silver is trading lower, influenced by broader market sentiment and concerns over the U.S. national debt reaching $40 trillion. It remains below its 20-day moving average.

23. aug 2026, 23:01 UTC

Gold/NZD is trading higher since Friday's close, maintaining a position above its 20-day moving average amid concerns over the U.S. national debt reaching $40 trillion.

23. aug 2026, 23:01 UTC

Gold/JPY is trading higher, reflecting a broader positive performance. The asset remains significantly above its 20-day moving average, indicating strong underlying momentum.

23. aug 2026, 23:01 UTC

Gold/HKD is higher today, reflecting a strong trend above its 20-day moving average. Earlier, it reached a high of 2.16% above Friday's close.

23. aug 2026, 23:01 UTC

Gold/SGD is higher in the current session, maintaining a gain above its 20-day moving average despite a slight pullback from earlier peaks.

Võrdlus sarnastega

Hinnamuutus

Theravance Biopharma Inc Prognoos

Hinnasiht

By TipRanks

-0.06% langus

12 kuu keskmine prognoos

Keskmine 17 USD -0.06%

Kõrge 17 USD

Madal 17 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Theravance Biopharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Theravance Biopharma Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.